Insights
Insights From Our Experts
Articles
Access Challenges for Severe Infectious Diseases
Content for this article was provided by EVERSANA’s Asia Pacific team. The global burden of infectious diseases is increasing, especially for severe diseases such as invasive aspergillosis, a rare infectious disease, which has a 90% mortality…
Ready or Not, Biosimilar Adalimumab Brings the Heat in 2023
Anticipated Growth in U.S. Biosimilars Market U.S. payers and other healthcare stakeholders have eagerly awaited the launch of biosimilar alternatives to high-cost originator products as a new cost-control lever. However, much of the U.S. healthcare market…
Case Study: Benchmarking Pathway-Specific Engagement with Health Plans & Organized Providers to Identify Best Practices
Tapping into primary market research and subject matter expertise can help uncover opportunities to more effectively meet their needs and position your brand for inclusion within their pathways. As stakeholders seek to leverage oncology clinical pathways…
Payer Oncology Access Management in 2022
Payers balance the severity of disease with the need to control high-dollar utilization. As pharmacy spend continues to rise, payers are seeking ways to manage costs in the highest cost therapeutic areas, including oncology. While there is appetite…
Brand Planning – Fitting Financial and Copay Services into Existing Models
EVERSANA’s Kevin O’Meara, Vice President, Patient Services Solutions, and Chris Lagoerio, Director, Revenue Management, presented a session, “Brand Planning – Fitting Financial and Copay Services into Existing Models,” at Informa Connect’s Copay, Reimbursement and Access Congress.…
Developing Best-in-class Copay Programs for Gross-to-Net
Importance of Copay Assistance Programs A copay assistance program is an invaluable strategic cost-saving tool that biopharmaceutical companies integrate into their patient services offering. These programs are used to support a brand’s value proposition, while offsetting…
Benchmarking Your Specialty Brand’s Rx Pull-Through Against Competitors In and Out of Your Network
Posted by
Reid Saleeby on October 12, 202210/12/22
As an executive at a specialty drug manufacturer, you know having access to your brand’s pull-through key performance indicators (KPIs) inside your network is only a very small part of a much bigger picture. In order…
AMA Scheduled to Deliberate Potential Approval of Additional Digital Medicine CPT Codes
As part of its upcoming meeting in mid-September, members of the American Medical Association’s (AMA) CPT Editorial Panel will consider several new Current Procedural Terminology (CPT) codes that identify digital diagnostic and therapeutic procedures. Between this…
Reimbursement Landscape for Digital Medicine Continues to Advance with CMS
The Centers for Medicare and Medicaid Services (CMS) recently announced several new payment and coding proposals that, once finalized, would recognize and advance the use of digital diagnostic and therapeutic modalities. In this week’s update, we…
Plasma derived medicinal products – What is the way forward?
Content for this article was contributed by the EVERSANA Asia Pacific team. Plasma-derived products have a long history of providing benefits, especially in fractions addressing coagulation. Plasma is a rich biological substance and one of the…